APAC hereditary cancer testing market report Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025–2030

APAC Hereditary Cancer Testing Market Overview

• The APAC Hereditary Cancer Testing Market is valued at USD 1.0 billion, based on a five-year historical analysis. This growth is primarily driven by increasing awareness of genetic disorders, advancements in next-generation sequencing technologies, and rising healthcare expenditure across the region. The demand for hereditary cancer testing is further fueled by the growing prevalence of hereditary cancers, the need for personalized medicine, and the expansion of early cancer detection programs. Notably, the region accounts for over 22% of the global hereditary cancer testing market revenue, reflecting robust demand for precision medicine and genetic risk assessment .
• Key players in this market include China, Japan, and India, which dominate due to their large populations, significant investments in healthcare infrastructure, and a rising number of genetic testing laboratories. These countries are also witnessing a surge in research and development activities, expansion of genetic counseling services, and government initiatives supporting preventive screening. The relatively low cost of testing and increased insurance coverage are improving access, while joint ventures and partnerships with global testing companies are accelerating market growth .
• In 2023, the Indian government implemented the National Health Policy, which emphasizes the importance of genetic testing in cancer prevention and management. This policy aims to enhance access to hereditary cancer testing services and promote awareness among healthcare providers and patients, thereby supporting the growth of the market. The National Health Policy, 2017 (Ministry of Health & Family Welfare, Government of India) mandates the integration of genetic testing for cancer risk assessment into public health programs, requiring healthcare institutions to provide genetic counseling and screening for high-risk populations .

APAC Hereditary Cancer Testing Market Segmentation

By Type:The market is segmented into various types of hereditary cancer tests, including BRCA1 and BRCA2 Testing, Lynch Syndrome Testing, Multigene Panel Testing, Single Gene Testing, Predictive Testing, and Diagnostic Testing. Among these, BRCA1 and BRCA2 Testing is the most dominant segment due to its critical role in breast and ovarian cancer risk assessment. The increasing awareness and demand for early detection of hereditary cancers have led to a surge in the adoption of this testing type. Multigene panel testing is rapidly gaining traction, particularly for colorectal and prostate cancers, as clinical guidelines increasingly recommend comprehensive genetic profiling for risk stratification and treatment planning .

By End-User:The end-user segmentation includes Hospitals, Diagnostic Laboratories, Research Institutions, Specialty Clinics, and Direct-to-Consumer Providers. Hospitals are the leading end-user segment, driven by their capacity to provide comprehensive healthcare services and the increasing integration of genetic testing into routine clinical practice. The growing trend of personalized medicine and the expansion of genetic counseling services are also contributing to the rising demand for hereditary cancer testing in hospital settings. Diagnostic laboratories are expanding their test menus and geographic coverage, while direct-to-consumer providers are leveraging telemedicine platforms to increase accessibility .

APAC Hereditary Cancer Testing Market Competitive Landscape

The APAC Hereditary Cancer Testing Market is characterized by a dynamic mix of regional and international players. Leading participants such as Myriad Genetics, Inc., Invitae Corporation, Fulgent Genetics, Inc., Guardant Health, Inc., Exact Sciences Corporation, Illumina, Inc., BGI Genomics Co., Ltd., Prenetics Limited, Gene Solutions (Vietnam), MedGenome Labs Ltd., Strand Life Sciences Pvt. Ltd., Ambry Genetics, Quest Diagnostics Incorporated, PathGen Diagnostics Pvt. Ltd., Natera, Inc. contribute to innovation, geographic expansion, and service delivery in this space. These companies leverage next-generation sequencing, strategic partnerships, and joint ventures to expand their hereditary cancer test offerings and geographic reach across APAC .

APAC Hereditary Cancer Testing Market Industry Analysis

Growth Drivers

• Increasing Prevalence of Hereditary Cancers:The incidence of hereditary cancers in the APAC region is rising, with approximately 1.5 million new cases reported annually. This increase is attributed to genetic predispositions, with breast and colorectal cancers being the most common. According to the World Health Organization, the prevalence of hereditary breast cancer is estimated at 5-10% of all breast cancer cases, driving demand for genetic testing services to identify at-risk individuals and facilitate early intervention.
• Advancements in Genetic Testing Technologies:The APAC market is witnessing rapid advancements in genetic testing technologies, with the introduction of next-generation sequencing (NGS) and CRISPR-based methods. In future, the global NGS market is projected to reach $5.5 billion, significantly impacting the accessibility and accuracy of hereditary cancer testing. These innovations enable comprehensive genomic profiling, allowing for more precise risk assessments and personalized treatment plans, thus enhancing patient outcomes and driving market growth.
• Rising Awareness and Demand for Personalized Medicine:The shift towards personalized medicine is gaining momentum in the APAC region, with a growing emphasis on tailored healthcare solutions. A survey by the Asia-Pacific Economic Cooperation indicates that 70% of healthcare professionals believe personalized medicine improves patient outcomes. This trend is further supported by the increasing availability of genetic counseling services, which educate patients about hereditary cancer risks, thereby boosting the demand for genetic testing and related services.

Market Challenges

• High Costs Associated with Genetic Testing:The cost of genetic testing remains a significant barrier in the APAC region, with prices ranging from $500 to $3,000 per test. This high cost limits accessibility for many patients, particularly in low-income areas. According to the World Bank, approximately 30% of the population in some APAC countries lives below the poverty line, making it challenging for these individuals to afford necessary genetic testing services, thus hindering market growth.
• Limited Access to Testing Facilities in Rural Areas:Access to genetic testing facilities is unevenly distributed across the APAC region, with rural areas facing significant challenges. Approximately 60% of the population in rural regions lacks access to specialized healthcare services, including genetic testing. This disparity is exacerbated by inadequate infrastructure and a shortage of trained professionals, which limits the ability of individuals in these areas to receive timely and necessary genetic testing, impacting overall market expansion.

APAC Hereditary Cancer Testing Market Future Outlook

The future of the APAC hereditary cancer testing market is poised for significant transformation, driven by technological advancements and increasing healthcare investments. As telehealth services expand, more patients will gain access to genetic counseling, enhancing testing uptake. Additionally, the focus on preventive healthcare will likely lead to increased demand for cost-effective genetic testing solutions, enabling broader population screening and early detection of hereditary cancers, ultimately improving patient outcomes and reducing healthcare costs.

Market Opportunities

• Expansion of Telehealth Services for Genetic Counseling:The rise of telehealth services presents a significant opportunity for genetic counseling in the APAC region. With an estimated 40% of patients preferring remote consultations, telehealth can bridge the gap in access to genetic testing, particularly in underserved areas, thereby increasing the overall testing rates and improving patient engagement in their healthcare decisions.
• Development of Cost-Effective Testing Solutions:There is a growing opportunity for companies to innovate and develop cost-effective genetic testing solutions. By leveraging advancements in technology, such as microarray and targeted sequencing, companies can reduce testing costs significantly. This approach can make genetic testing more accessible to a broader population, particularly in developing countries, thus driving market growth and improving early detection rates.